IMPACT Therapeutics Inc is a China-based company primarily engaged in the research, development, and commercialization of pharmaceutical products. The Company is principally engaged in the research and development of synthetic lethality-based precision anti-cancer therapies. The Company's product pipeline is primarily composed of Senaparib, as well as novel antibody-drug conjugates (ADCs) and degrader candidates. The Company distributes its products within the domestic market and to overseas markets.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
13/08/26	HK$12.88	-1.98%	340,600
12/08/26	HK$13.14	+0.15%	858,033
11/08/26	HK$13.12	+2.02%	1,163,292
10/08/26	HK$12.86	+2.80%	778,550
07/08/26	HK$12.51	+4.16%	597,505

Delayed Quote Hong Kong S.E.

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

11.29CNY

Average target price

28.52CNY

Spread / Average Target

+152.54%

Consensus

Net sales - Rate of surprise

Company calendar

Delayed Hong Kong S.E. 06:59:09 13/08/2026 +03			5-day change	1st Jan Change
12.88 ^HKD	-1.98%		+7.24%	-

07-31	IMPACT Therapeutics, Inc and Pharmanovia Enter Exclusive License Agreement For Senaparib In Europe, Middle East And North Africa, Australia And New Zealand	CI
07-28	IMPACT Therapeutics, Inc Announces IMP3201 As A Preclinical Candidate, A First-In-Class CEACAM5-Targeted Dual-Payload ADC	CI

Market Cap	3.12B 3.63B 462M 401M 375M 342M 644M 44.1B 654M 4.41B 1.73B 22.08B 1.74B 1.7B 73.64B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	2.28B 2.65B 338M 292M 274M 250M 470M 32.19B 477M 3.22B 1.26B 16.12B 1.27B 1.24B 53.75B	EV / Sales 2026 *	7.92x	EV / Sales 2027 *	1.95x
Free-Float	53.13%	Yield 2026 *	-	Yield 2027 *	-

07-31	IMPACT Therapeutics, Inc and Pharmanovia Enter Exclusive License Agreement For Senaparib In Europe, Middle East And North Africa, Australia And New Zealand	CI
07-28	IMPACT Therapeutics, Inc Announces IMP3201 As A Preclinical Candidate, A First-In-Class CEACAM5-Targeted Dual-Payload ADC	CI
07-27	Impact Therapeutics Nominates Preclinical Candidate for GI Cancers	MT
07-21	Impact Therapeutics Announces Clinical Data for Senaparib, IMP4297, and IMP1707 Accepted for Poster Presentation at 2026 ESMO Congress	CI
06-08	Impact Therapeutics Nets HK$120 Million From Full Exercise of IPO Overallotment Option	MT
06-02	Impact Therapeutics, Inc Presents Phase 1/2 Clinical Data for Imp1734 At 2026 Asco Annual Meeting	CI
05-13	Hong Kong Stocks Eke Out Gains; Metis TechBio, Impact Therapeutics Shine on Debut	MT
05-13	Impact Therapeutics Jumps 77% in Hong Kong Trading Debut	MT
05-13	Impact Therapeutics Nets HK$759.5 Million From Hong Kong IPO Ahead of Debut	MT
05-12	IMPACT Therapeutics, Inc has completed an IPO in the amount of HKD 843.7377 million.	CI
05-12	Impact Therapeutics says final offer price under global offering of HK$20.10 per H share	RE
05-05	IMPACT Therapeutics, Inc has filed an IPO in the amount of HKD 913.20964 million.	CI
05-05	IMPACT Therapeutics, Inc Reports Earnings Results for the Full Year Ended December 31, 2025	CI

1 day	-1.98%
1 week	+7.24%
Current month	-2.65%
1 month	-28.68%

IMPACT Therapeutics, Inc Stock

Stocks

7630

CNE100007LG4

Biotechnology & Medical Research

Valuation: IMPACT Therapeutics, Inc

Chart: IMPACT Therapeutics, Inc

Latest news : IMPACT Therapeutics, Inc

Press Releases: IMPACT Therapeutics, Inc

Quotes and Performance

Course Extremes

Managers and Directors: IMPACT Therapeutics, Inc

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Net sales - Rate of surprise

1 week	11.8	14.5
1 month	10.31	18.85
Current year	10.31	47.98
1 year	10.31	47.98
3 years	10.31	47.98
5 years	10.31	47.98
10 years	10.31	47.98

Manager	Title	Age	Since
Sui Xiong Cai CEO	Chief Executive Officer	69	01/06/2014
Hui Jun Deng DFI	Director of Finance/CFO	51	01/05/2024
Yan Hua Xu CTO	Chief Tech/Sci/R&D Officer	44	01/01/2025

Director	Title	Age	Since
Ye Tian BRD	Director/Board Member	69	01/06/2014
Sui Xiong Cai BRD	Director/Board Member	69	01/06/2014
Ning Ma BRD	Director/Board Member	44	01/03/2025

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IMPACT THERAPEUTICS, INC	-1.98%	+7.24%	-	-	462M
LONZA GROUP AG	-1.60%	+0.86%	+3.70%	+14.41%	48.72B
REVOLUTION MEDICINES, INC.	-0.14%	+4.03%	+482.13%	+584.43%	43.99B
BEONE MEDICINES AG	-0.06%	+9.62%	+24.63%	+81.63%	40.82B
IQVIA HOLDINGS INC.	-0.87%	+2.40%	+30.01%	+9.95%	39.79B
CELLTRION, INC.	-4.04%	+6.15%	+23.03%	+48.00%	32.7B
MEDPACE HOLDINGS, INC.	-1.41%	+1.57%	+29.98%	+123.68%	16.66B
ASCENDIS PHARMA A/S	+0.35%	+4.61%	-	-	16.84B
EUROFINS SCIENTIFIC SE	-0.43%	-0.11%	+4.22%	+20.83%	13.95B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.84%	+9.07%	+86.17%	+32.60%	13.58B
Average	-0.93%	+3.75%	+85.48%	+114.44%	26.75B
Weighted average by Cap.	-1.00%	+3.93%	+104.21%	+137.91%

	2026 *	2027 *
Net sales	288M 335M 42.64M 36.94M 34.61M 31.57M 59.35M 4.07B 60.26M 407M 159M 2.04B 160M 157M 6.79B	941M 1.1B 140M 121M 113M 103M 194M 13.31B 197M 1.33B 521M 6.67B 524M 513M 22.23B
Net income	-	-
Net Debt	-842M -980M -125M -108M -101M -92.48M -174M -11.91B -177M -1.19B -466M -5.97B -469M -459M -19.89B	-1.29B -1.5B -191M -165M -155M -141M -266M -18.21B -270M -1.82B -713M -9.12B -717M -701M -30.4B